Mpox Vaccine Rollout Enters Its Stockpile Era as Ebola and Marburg Compete for Attention

Key Takeaway: The mpox vaccine rollout has moved from emergency donation drives to a standing stockpile of up to 2 million doses, launched on 27 August 2026 under the WHO-hosted ICG on Vaccine Provision. Africa CDC delivered more than 5 million doses to 16 countries by early 2026 but fell short of its 6-million-dose target, and a 6,250-case Bundibugyo Ebola outbreak in the DRC now competes for the same financing.

ADDIS ABABA, 23 October 2026 — The mpox vaccine rollout entered a new operating model this year, with up to 2 million doses now pre-contracted under the WHO-hosted International Coordinating Group (ICG) on Vaccine Provision, while Africa CDC — whose continental mandate runs through the kind of world affairs coverage that shapes donor attention — simultaneously manages a Bundibugyo Ebola outbreak exceeding 6,250 cases. One budget, three pathogens.

About this reporting: This analysis draws on published statements and situation reporting from Africa CDC, the World Health Organization, Gavi and CEPI dated between September 2025 and October 2026. Case and dose figures carry their as-of dates and attributions. No figure has been estimated or extrapolated.

What Changed in the Mpox Vaccine Rollout

The mpox vaccine rollout changed its financing and allocation model, not its scale. WHO ended the mpox public health emergency of international concern in September 2025, therefore money shifted out of surge appeals and into routine preparedness budgets. The 2024-25 Access and Allocation Mechanism depended on bilateral donations, which is why delivery timing tracked donor announcements rather than epidemiological need. Countries with the heaviest case burden waited on pledges made in capitals thousands of kilometres away, and that sequencing problem is the specific failure the new architecture was built to correct.

The consequence of the 27 August 2026 ICG stockpile launch is that doses are pre-contracted and manufacturer-held, which means allocation decisions are now made against a standing inventory rather than against a pledge schedule. Mpox transmission in Central Africa has continued at endemic levels through 2026, so demand did not disappear when the emergency label did.

What the Global Mpox Vaccine Stockpile Actually Is

Definition: The global mpox vaccine stockpile is a centrally allocated reserve of up to 2 million doses, launched on 27 August 2026 under the International Coordinating Group on Vaccine Provision, with WHO as secretariat and Gavi as financier. Doses are held at manufacturer facilities and released on country request.

How the mpox vaccine stockpile works

• Launched 27 August 2026 under the ICG on Vaccine Provision, with WHO as secretariat
• Target volume of up to 2 million doses, held at manufacturer facilities rather than in-country
• Financed by Gavi, the Vaccine Alliance, covering procurement and delivery support
• Partner agencies on the ICG: WHO, UNICEF, Médecins Sans Frontières and the IFRC
• Covers both outbreak response and preventive vaccination of high-risk groups
• Replaces the donation-dependent Access and Allocation Mechanism used in 2024-25

The manufacturer-held design matters because doses sit inside the supply chain rather than in national cold stores, which means carrying costs fall on the mechanism and not on ministries of health. Low-income countries therefore no longer finance inventory they might never deploy. Gavi funding covers procurement and delivery support rather than doses alone, and UNICEF, MSF and the IFRC sit on the ICG alongside WHO — as a result, release decisions involve the agencies that actually run the last mile.

Africa CDC’s Rollout Record and Where It Fell Short

Africa CDC deployed more than 5 million mpox vaccine doses to 16 countries by early 2026, according to Africa CDC. The continental target was 6 million doses. Delivery therefore landed roughly a sixth short. The DRC absorbed the largest share of doses because it carried the heaviest confirmed case burden on the continent. The shortfall was driven by distribution constraints rather than by an absence of available product, which is precisely why the 2026 stockpile model was designed around allocation speed rather than around volume alone. The distinction has operational weight: a supply problem is solved by buying more, while a distribution problem is solved by restructuring who decides and who pays for the last mile.

Three blockers that slowed delivery

1. Regulatory bottlenecks — national authorisation and import review ran on separate national timetables, resulting in doses held at ports while approvals cleared.
2. Vaccine hesitancy in affected districts — uptake lagged because mpox was framed as a stigmatised condition, resulting in unused allocations that expired or were reassigned.
3. Financing gaps for delivery, not doses — donated vaccine arrived without matched cold-chain and staffing money, which means campaigns stalled after arrival rather than before it.

The 2026 Bundibugyo Ebola Outbreak in the DRC

The Bundibugyo Ebola outbreak is among the DRC’s most serious on record, with more than 6,250 cases and more than 3,000 deaths across 60 health zones as of September 2026, per Africa CDC situation reporting. The DRC government requested emergency vaccine from the global Ebola ICG stockpile in August 2026. The ICG released 70,000 doses of the Ervebo vaccine in response.

Ervebo is licensed against Zaire ebolavirus, not Bundibugyo virus, therefore 20,000 doses were allocated to a Phase 3 trial testing cross-strain efficacy while 50,000 went to frontline health workers as a protective measure. As a result, DRC Ebola vaccination functions as a response operation and a clinical study at the same time, which raises the personnel burden per dose delivered — trial monitors, consent procedures and data capture staff are required alongside vaccinators.

Marburg Virus and the Countermeasure Gap

No Marburg vaccine is licensed anywhere as of October 2026, according to WHO. CEPI and Africa CDC redirected resources to a Marburg virus outbreak in Ethiopia and initiated Phase 2 vaccine trials to support containment. Because no product is licensed, every deployment runs under a clinical protocol, which requires ethics approval, informed consent procedures and trial monitoring staff. As a result, a Marburg response consumes more technical capacity per person vaccinated than an mpox campaign using an authorised vaccine. That ratio is the hidden cost of the countermeasure gap, and it falls on the same continental workforce handling two other activations.

What the 2025-2026 Trial Data Shows

The evidence base widened in 2025 and 2026, which matters because mpox transmission in Central Africa involves children and pregnant women who sat outside earlier product labelling.

Trial and effectiveness readouts, 2025-2026

• October 2025, CEPI: topline data indicated the MVA-BN vaccine is safe and produces a non-inferior immune response in children aged 2-11
• 2026, Africa CDC and partners: LC16m8 real-world effectiveness studies under way in African populations
• 2026: studies assessing mpox vaccine safety in pregnancy — the remaining evidence gap for high-burden districts
• August 2026, ICG: Phase 3 trial of Ervebo against Bundibugyo virus, using 20,000 of the 70,000 released doses
• 2026, CEPI and Africa CDC: Phase 2 Marburg vaccine trials initiated during the Ethiopia outbreak

Paediatric immunogenicity data removes the main clinical objection to vaccinating under-12s, therefore future stockpile allocations can target entire household contact networks rather than adults alone. Pregnancy safety data remains the thinnest segment of the evidence base, and that gap constrains campaign design in exactly the high-burden districts where household transmission dominates.

Why Three Outbreaks at Once Strains One Budget

Mpox, Bundibugyo Ebola and Marburg draw on the same continental pool of field epidemiologists, cold-chain capacity and emergency financing, therefore every simultaneous activation forces a triage decision. The mpox vaccine rollout now competes with a viral haemorrhagic fever response carrying a far higher case-fatality rate, which means acute mortality pulls trained staff away from preventive campaigns. Dr Emanuele Capobianco, Director for Global Health Security at Gavi, said in September 2026 that the new mpox stockpile builds directly on the 2024 experience in which African countries faced severe difficulty securing doses — an assessment that locates the stockpile’s purpose in a specific, documented failure rather than in general preparedness language.

Africa CDC’s Emergency Response and Resilience Strategy mandates deployment of personnel, financing and materials within the first 48 hours of an outbreak, and that clock is what makes concurrent activation expensive, because surge teams cannot be sequenced across emergencies. A June 2026 peer-reviewed assessment of institutionalising public health emergency response in Africa concluded that managing mpox, Marburg and Ebola together demonstrated continental political authority, technical competence and operational speed. The equity question has consequently moved: standing stockpiles address access, while delivery financing remains unresolved.

Frequently Asked Questions

What is the global mpox vaccine stockpile?

It is a centrally allocated reserve of up to 2 million doses, launched on 27 August 2026 under the ICG on Vaccine Provision, with WHO as secretariat and Gavi as financier. Doses are held at manufacturer facilities and released on country request, which is why deployment no longer waits on individual donor pledges being announced and fulfilled.

How many mpox vaccine doses has Africa CDC delivered?

More than 5 million doses to 16 countries by early 2026, per Africa CDC, against a 6-million-dose continental target. The gap was driven by regulatory bottlenecks at national level, hesitancy in affected districts and unmatched delivery financing — not by a shortage of available doses.

Why did the mpox public health emergency end?

WHO ended the mpox PHEIC in September 2025 because case trends and response capacity no longer met the criteria for an emergency of international concern. The consequence was financial: funding moved into routine preparedness budgets, which is what made a standing stockpile necessary rather than optional.

How large is the 2026 Ebola outbreak in the DRC?

More than 6,250 cases and more than 3,000 deaths across 60 health zones as of September 2026, caused by Bundibugyo virus. The ICG released 70,000 Ervebo doses in August 2026 following a formal request from the DRC government for emergency supply.

Does the Ervebo vaccine protect against Bundibugyo virus?

Not established. Ervebo is licensed against Zaire ebolavirus only, therefore 20,000 of the 70,000 released doses were assigned to a Phase 3 trial testing cross-strain efficacy against Bundibugyo virus, while the remaining 50,000 doses went to frontline health workers.

Is there a vaccine for Marburg virus?

No licensed Marburg vaccine exists as of October 2026. CEPI and Africa CDC initiated Phase 2 trials during the Ethiopia outbreak, which means any deployment runs under a clinical protocol and consumes more technical staff per person vaccinated than a licensed-product campaign.

What is the difference between Ebola and Marburg?

Both are filoviruses causing viral haemorrhagic fever, but they are distinct viruses with separate countermeasure pipelines. The operational difference is licensure: Ebola has a licensed vaccine for the Zaire strain, Marburg has none, therefore Marburg responses depend entirely on trial protocols and their associated staffing.

Is the mpox vaccine safe for children?

October 2025 topline data from CEPI indicated MVA-BN is safe and produces a non-inferior immune response in children aged 2-11. This evidence supports extending campaigns to household contacts. Pregnancy safety data remains the thinner segment of the evidence base as of October 2026.

Who funds the mpox vaccine stockpile?

Gavi, the Vaccine Alliance, finances the stockpile, with WHO acting as ICG secretariat and UNICEF, MSF and the IFRC as partner agencies. Gavi funding covers procurement and delivery support rather than doses alone, which addresses the delivery-financing gap seen in 2024-25.

Why do simultaneous outbreaks slow vaccine rollout?

Because mpox, Ebola and Marburg draw on the same epidemiologists, cold chain and emergency financing. The mpox vaccine rollout loses personnel to higher-fatality responses. Africa CDC’s 48-hour deployment mandate under its Emergency Response and Resilience Strategy prevents sequencing surge teams, resulting in triage across concurrent emergencies rather than orderly queuing.

What This Reporting Does Not Settle

The 2-million-dose figure is a target volume, not confirmed delivered inventory, and the ICG has not published a dose-by-dose allocation ledger. Cross-strain Ervebo efficacy against Bundibugyo virus is unresolved pending Phase 3 results, therefore the 50,000 health-worker doses carry uncertain protective value. Outbreak case and death counts in the DRC are provisional and subject to retrospective revision, because surveillance across 60 affected health zones is incomplete. Critics also argue that centralised stockpiling concentrates allocation authority in Geneva-based institutions rather than African regulators — a different equity problem from dose scarcity, and one the stockpile model does not resolve.

Open questions as of 23 October 2026

• Whether the full 2 million stockpile doses have been contracted or only pledged
• Whether Ervebo confers cross-protection against Bundibugyo virus, pending the Phase 3 readout

The Test Ahead

The mpox vaccine rollout no longer fails for want of doses, because the ICG stockpile removed the scarcity bottleneck that defined 2024. What now determines coverage is delivery financing and staff availability.

Both are being consumed by a 6,250-case Bundibugyo Ebola outbreak and an unlicensed Marburg response that runs on trial protocols. The measurable tests are the Phase 3 cross-strain trial readout and the first full-year ICG allocation accounting.

References

• Africa CDC — news and continental vaccination reporting
• Africa CDC — Ebola disease and Bundibugyo virus situation reporting
• Gavi, the Vaccine Alliance — VaccinesWork
• World Health Organization — news room and ICG on Vaccine Provision
• World Health Organization — Disease Outbreak News and PHEIC determinations
• World Health Organization — Marburg virus disease fact sheet
• CEPI — news and trial readouts
• Taylor & Francis — June 2026 assessment of institutionalising public health emergency response in Africa